Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mirum Pharmaceuticals Inc
(NQ:
MIRM
)
24.03
-0.41 (-1.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
565,910
Open
24.54
Bid (Size)
23.50 (1)
Ask (Size)
25.65 (1)
Prev. Close
24.44
Today's Range
23.83 - 24.95
52wk Range
23.14 - 35.56
Shares Outstanding
38,297,975
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
May 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
May 29, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-19.95%
-19.95%
1 Month
+0.04%
+0.04%
3 Month
-13.59%
-13.59%
6 Month
-25.72%
-25.72%
1 Year
-7.83%
-7.83%
More News
Read More
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
May 18, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings For Mirum Pharmaceuticals
May 09, 2024
Via
Benzinga
Analyst Ratings For Mirum Pharmaceuticals
April 17, 2024
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
May 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals
March 18, 2024
Via
Benzinga
Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know
February 29, 2024
Via
Benzinga
Mirum Pharmaceuticals: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
May 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
May 01, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
April 02, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Preview: Mirum Pharmaceuticals's Earnings
February 27, 2024
Via
Benzinga
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
March 28, 2024
Via
Benzinga
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy
March 14, 2024
Via
Benzinga
Exposures
Product Safety
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
March 13, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
March 05, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
February 29, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
February 28, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.